Paratek Pharmaceuticals, Inc.

Informe acción NasdaqGM:PRTK

Capitalización de mercado: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Salud financiera de hoja de balance de Paratek Pharmaceuticals

Salud financiera controles de criterios 1/6

Paratek Pharmaceuticals has a total shareholder equity of $-201.4M and total debt of $258.3M, which brings its debt-to-equity ratio to -128.3%. Its total assets and total liabilities are $145.8M and $347.2M respectively.

Información clave

-128.3%

Ratio deuda-patrimonio

US$258.33m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$42.69m
Patrimonio-US$201.36m
Total pasivoUS$347.16m
Activos totalesUS$145.79m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Apr 17
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals: Patience Is Wearing Thin

Aug 24

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Aug 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

Jan 03

The Play On Paratek Pharmaceuticals

Oct 18

Peeking Back In On Paratek Pharmaceuticals

Aug 07

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Jun 16

Paratek shares rise after FDA approves NUZYRA oral only dosing regimen

Jun 01

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Apr 27

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Mar 01
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Feb 01
Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment

Jan 04

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

Dec 01

Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Análisis de la situación financiera

Pasivos a corto plazo: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Pasivo a largo plazo: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Historial y análisis de deuda-patrimonio

Nivel de deuda: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducción de la deuda: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PRTK has sufficient cash runway for more than a year based on its current free cash flow.

Pronóstico de cash runway: Insufficient data to determine if PRTK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Descubre empresas con salud financiera